

DEAR PHYSICIAN: This letter is being provided as a sample to help you with your payor interactions concerning reimbursement for the administration of XIAFLEX® (collagenase clostridium histolyticum). Use of this document does not guarantee coverage or reimbursement. For example, coding is a clinical decision and Endo provides codes for physician reference only. As a healthcare professional, you are solely responsible for providing accurate information to third-party payors. If there is any information in this document that does not accurately reflect your practices, it should be modified to appropriately represent your particular circumstances.

INDICATION

XIAFLEX® is indicated for the treatment of adult patients with Dupuytren's contracture with a palpable cord.

IMPORTANT SAFETY INFORMATION FOR XIAFLEX

- XIAFLEX is contraindicated in patients with a history of hypersensitivity to XIAFLEX or to collagenase used in any other therapeutic application or application method
- In the controlled and uncontrolled portions of clinical trials in Dupuytren's contracture, flexor tendon ruptures occurred after XIAFLEX injection. Injection of XIAFLEX into collagen-containing structures such as tendons or ligaments of the hand may result in damage to those structures and possible permanent injury such as tendon rupture or ligament damage. Therefore, XIAFLEX should be injected only into the collagen cord with a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint contracture, and care should be taken to avoid injecting into tendons, nerves, blood vessels, or other collagen-containing structures of the hand. When injecting a cord affecting a PIP joint of the fifth finger, the needle insertion should not be more than 2 to 3 mm in depth and avoid injecting more than 4 mm distal to the palmar digital crease
- Other XIAFLEX-associated serious local adverse reactions in the controlled and uncontrolled portions of the clinical studies included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear). In a historically controlled post-marketing trial, the incidence of skin laceration (22%) was higher for subjects treated with two concurrent injections of XIAFLEX compared with subjects treated with up to three single injections in the placebo-controlled premarketing trials (9%). Post-marketing cases of skin laceration requiring skin graft after finger extension procedures and local skin and soft-tissue necrosis, some requiring skin grafting, or other surgical interventions including finger amputation have been reported. Signs or symptoms that may reflect serious injury to the injected finger/hand should be promptly evaluated because surgical intervention may be required
- Cases of syncope and presyncope have been reported in the post-marketing period in patients treated with XIAFLEX. In most cases in patients with Dupuytren's contracture, the injection procedure, finger extension procedure, or pain following the procedures were reported as potential triggers for the events, suggesting a vasovagal mechanism. Most, but not all, cases occurred in the immediate treatment period (injection or finger extension procedure) or within 1 to 2 days following the injection or finger extension procedure. If presyncopal symptoms occur, patients should remain recumbent until symptoms resolve. Syncope may be associated with bodily injuries, including concussion, head abrasion, and other accidental injuries
- In the controlled portions of the clinical trials in Dupuytren's contracture, a greater proportion of XIAFLEX-treated patients (15%) compared to placebo-treated patients (1%) had mild allergic reactions (pruritus) after up to 3 injections. The incidence of XIAFLEX-associated pruritus increased after more XIAFLEX injections in patients with Dupuytren's contracture
- Because XIAFLEX contains foreign proteins, severe allergic reactions to XIAFLEX can occur. Anaphylaxis was reported in a post-marketing clinical trial in one patient who had previous exposure to XIAFLEX for the treatment of Dupuytren's contracture. Healthcare providers should be prepared to address severe allergic reactions following XIAFLEX injections
- In the XIAFLEX trials in Dupuytren's contracture, 70% and 38% of XIAFLEX-treated patients developed an ecchymosis/contusion or an injection site hemorrhage, respectively. Patients with abnormal coagulation (except for patients taking low-dose aspirin, eg, up to 150 mg per day) were excluded from participating in these studies. Therefore, the efficacy and safety of XIAFLEX in patients receiving anticoagulant medications (other than low-dose aspirin, eg, up to 150 mg per day) within 7 days prior to XIAFLEX administration is not known. In addition, it is recommended to avoid use of XIAFLEX in patients with coagulation disorders, including patients receiving concomitant anticoagulants (except for low-dose aspirin)
- In the XIAFLEX clinical trials for Dupuytren's contracture, the most common adverse reactions reported in ≥25% of patients treated with XIAFLEX and at an incidence greater than placebo were edema peripheral (eg, swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the injected extremity
- Post-marketing experience – Syncope and presyncope have been reported in patients treated with XIAFLEX. Most, but not all, cases occurred in the immediate treatment period or within 1 to 2 days following injection. Bodily injuries associated with the syncopal events have been reported

Click for full [Prescribing Information](#) and [Medication Guide](#).

[Date]

[Insurance contact name]
[Insurance contact title]
[Name of insurance
company] [Insurance street
address]
[City, State ZIP]

Re: Denied Injection Claim Appeal Request for XIAFLEX® (collagenase clostridium histolyticum)

Patient name: **[First and last
name]** Patient date of birth: **[XX/XX/
XXXX]**
SS #: **[XXX-XX-XXXX]**
Insurance ID #:
[XXXXXXXXXXXXXXXXXX] Group #:
[XXXXXXXX]
Claim #: **[XXXXXXXXXX]**

Dear **[Insurance contact name]**:

I am writing on behalf of my patient, **[patient's name]**, to request reconsideration of a denied claim for XIAFLEX®. XIAFLEX® is indicated for the treatment of adult patients with Dupuytren's contracture with a palpable cord. XIAFLEX® was provided to **[patient's name]** on **[date of service]** to treat **[his/her]** Dupuytren's contracture.

You have indicated that XIAFLEX® is not eligible for coverage under the patient's health insurance plan due to **[reason for denial from explanation of benefits]**. **[If due to injection of 2 joints/cords during a treatment visit, include following line:]** On October 20, 2014, the FDA-approved Prescribing Information for XIAFLEX® was revised to allow for the treatment of up to 2 joints/cords in the same hand at a treatment visit.

After a thorough review of the patient's history and condition, I have reconfirmed that treatment with XIAFLEX® was medically necessary for **[patient's name]**. To further support the medical necessity of this patient's treatment with XIAFLEX®, I am including information on the patient's history and diagnosis, as well as additional information on the patient's condition.

[Reasons why XIAFLEX® was prescribed, information on patient's condition, specific joint(s) affected, number of cords and degrees of contracture for metacarpophalangeal/proximal interphalangeal joint release; patient's medical records, impact on range of motion.]

Based on the preceding facts, I believe treatment with XIAFLEX® was appropriate and medically necessary for this patient. I would appreciate reconsideration of this claim.

XIAFLEX® may be billed using the following codes:

Procedure Codes (CPT® codes) designated by the American Medical Association (AMA)

20527: Injection, enzyme (eg, collagenase), palmar fascial cord (ie, Dupuytren's contracture)

20527-XX*: Injection, enzyme (eg, collagenase), palmar fascial cord (ie, Dupuytren's contracture)—distinct procedural service

**The codes used to describe single-cord treatment of adult patients with Dupuytren's contracture with a palpable cord may also be used to describe treatment for up to 2 joints/cords in the same hand. Modifiers may be necessary to ensure services are processed and paid correctly.*

Modifier -59 Distinct Procedural Service for Medicare. Under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-Evaluation and Management (E/M) services performed on the same day. Refer to full AMA coding guidance. Modifier -59 is necessary for the injection procedure.¹

Modifier -51 Multiple Procedures for Commercial Payors. When multiple procedures, other than E/M services, Physical Medicine and Rehabilitation services or provision of supplies (eg, vaccines), are performed at the same session by the same individual, the primary procedure or service may be reported as listed. The additional procedure(s) or service(s) may be identified by appending modifier -51 to the additional procedure or service code(s). Note: This modifier should not be appended to designated "add-on" codes.²

If you have any further questions, please feel free to contact my office to discuss this case. Thank you in advance for your immediate attention to this request.

Sincerely,

[Physician's name and credentials]

[Title]

[Name of practice]

[Street address]

[City, State ZIP]

[Phone number]

Enclosures:

[Patient medical records/chart notes]

[XIAFLEX® (collagenase clostridium histolyticum) full Prescribing Information]

References: 1. Centers for Medicare and Medicaid Services. Proper use of modifiers 59 & -X{EPSU}. <https://www.cms.gov/files/document/proper-use-modifiers-59-xepsu.pdf>. Accessed August 9, 2022. 2. OPTUM306. Modifier 51 Coding website. https://www.encoderpro.com/epro/allModifiersHandler.do?_k=101*0&_a=listRelated&menu=4. Accessed August 9, 2022.